Recombinant Human EGFR vIII (C-6His)

Description

EnkiLife provides the Recombinant Human EGFR vIII (C-6His) protein,aslo know as Epidermal growth factor receptor,EGFR,Proto-oncogene c-ErbB-1,Receptor tyrosine-protein kinase erbB-1,EGFR, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Epidermal Growth Factor Receptor/Receptor Tyrosine Protein Kinase ErbB1 is produced by our Mammalian expression system and the target gene encoding Leu25-Ser378 is expressed with a 6His tag at the C-terminus.Accession:NP_001333870. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:39.7 KDa. Background:The EGFR subfamily of receptor tyrosine kinases is composed of EGFR, ErbB2, ErbB3 and ErbB4. The EGFR shares 43% - 44% aa sequence identity with the ECD of human EGFR subfamily. All these family members are type I transmembrane glycoproteins with an extracellular ligand binding domain. The extracellular ligand binding domain is containing two cysteine-rich domains separated by a spacer region and a cytoplasmic domain containing a membrane-proximal tyrosine kinase domain. Ligand binding could induce EGFR homodimerization and heterodimerization with ErbB2, resulting in cell signaling, heterodimerization tyrosine phosphorylation and kinase activation. It can bind EGF, amphiregulin, TGF-alpha, betacellulin, epiregulin, HB-EGF, epigen, and so on. Its signaling regulates multiple biological functions including cell proliferation, differentiation, motility, and apoptosis. EGFR can also be recruited to form heterodimers with the ligand-activated ErbB3 or ErbB4. EGFR is overexpressed in different tumors. Several anti-cancer drugs use EGFR as target.